Medication info
Avoltan A Plus Tablets 5/80/20 Milligrams

Avoltan A Plus Tablets 5/80/20 Milligrams

Prescription medicationTabletOral
Ingredient · strength
Amlodipine Besylate›6.94mg / 1 tabletValsartan›80mg / 1 tabletAtorvastatin Calcium Hydrate›21.7mg / 1 tablet
Manufacturer / importer
Dongu Bio Pharmaceutical Co., Ltd.
Appearance
Pale orange, oval film-coated tablet
Packaging
30 tablets per bottle
Approval status
Active

MFDS item code 202006655 · Approved 2020.09.25 · Insurance code 657308440

Summary

Main use
Treatment of hypertension, improvement of dyslipidemia, prevention of cardiovascular disease
Who takes it
Adults
Adult dose
Take 1 tablet once daily with water. If possible, it is recommended to take it at the same time each day (e.g., in the morning). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the amlodipine/valsartan combination and atorvastatin. Patients taking the amlodipine/valsartan combination together with atorvastatin as separate tablets may switch to this medicine (a combination tablet containing the same amounts of each active ingredient) for convenience. ▷ Amlodipine/valsartan combination It is recommended that the dose of the individual component (amlodipine or valsartan) be adjusted before administering the amlodipine/valsartan combination. However, if blood pressure is not controlled with monotherapy using the individual components, switching directly to the amlodipine/valsartan combination may be considered as follows. ㆍ5/80 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 80 mg monotherapy. ㆍ5/160 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 160 mg monotherapy. ㆍ10/160 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or valsartan 160 mg monotherapy, or with 5/160 mg. - Patients with renal impairment: No dosage adjustment is required in patients with mild or moderate renal impairment (creatinine clearance 10mL/min or more); however, the amlodipine/valsartan combination should not be administered to patients with severe renal impairment (creatinine clearance less than 10mL/min) or patients on dialysis. Monitoring of potassium levels and creatinine is recommended in patients with moderate renal impairment. - Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of valsartan should not exceed 80mg. Do not administer the amlodipine/valsartan combination to patients with severe hepatic impairment, biliary cirrhosis, biliary obstruction, or cholestasis. - Patients aged 65 years or older: Use caution when increasing the dose. ▷ Atorvastatin Before and during treatment with atorvastatin, patients should follow a standard cholesterol-lowering diet. Atorvastatin may be taken at any time of day, with or without food. 1. Dyslipidemia The recommended initial dose is 10 mg of atorvastatin once daily. However, patients who require a greater reduction in LDL cholesterol may start with 20 mg or 40 mg once daily (40 mg is for patients requiring an LDL cholesterol reduction of 45 % or more). This medicine is administered at a dose of 10 ~ 80 mg once daily. The initial and maintenance doses should be individualized according to the patient's characteristics, taking into account the treatment goal and response. Lipid levels should be analyzed within 2 ~ 4 weeks after treatment initiation and/or dose titration, and the dose should be adjusted accordingly. Because the goal of treatment is to lower LDL cholesterol, it is recommended that LDL cholesterol be used when initiating treatment and assessing the treatment response. However, if LDL cholesterol levels are unavailable, total cholesterol should be used to monitor the treatment response. Patients with homozygous familial hypercholesterolemia The dose is 10 ~ 80 mg once daily. Administer this medicine in combination with other lipid-lowering treatments (e.g., LDL apheresis), or when such treatments are not possible. - Patients with renal impairment: Renal disease does not affect the plasma concentration of atorvastatin or its LDL cholesterol-lowering effect; therefore, no dosage adjustment is necessary. - Older adults: The efficacy and safety in patients aged 70 years or older are similar to those in the general adult population.

Ingredients

Manufacturer
Dongu Bio Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension, improvement of dyslipidemia, prevention of cardiovascular disease

  • Essential hypertension
  • myocardial infarction
  • stroke
  • chronic stable angina
  • retinopathy
  • albuminuria
  • type 2 diabetes
  • non-fatal myocardial infarction
  • fatal and non-fatal stroke
  • congestive heart failure
  • angina
  • dyslipidemia
View approved original text

This medication is used for patients who require simultaneous administration of amlodipine/valsartan combination therapy and atorvastatin. The amlodipine/valsartan combination aids in managing blood pressure in patients with essential hypertension whose blood pressure is not sufficiently controlled with monotherapy. Atorvastatin reduces the risk of cardiovascular diseases, especially the occurrence of complications related to myocardial infarction, stroke, and vascular surgeries. It also improves blood cholesterol and triglyceride levels in patients with dyslipidemia, contributing ultimately to the prevention of cardiovascular diseases. Thus, this medication is used to improve cardiovascular health by managing both blood pressure and cholesterol levels.

How to take

Adult dose

Take 1 tablet once daily with water. If possible, it is recommended to take it at the same time each day (e.g., in the morning). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the amlodipine/valsartan combination and atorvastatin. Patients taking the amlodipine/valsartan combination together with atorvastatin as separate tablets may switch to this medicine (a combination tablet containing the same amounts of each active ingredient) for convenience. ▷ Amlodipine/valsartan combination It is recommended that the dose of the individual component (amlodipine or valsartan) be adjusted before administering the amlodipine/valsartan combination. However, if blood pressure is not controlled with monotherapy using the individual components, switching directly to the amlodipine/valsartan combination may be considered as follows. ㆍ5/80 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 80 mg monotherapy. ㆍ5/160 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 160 mg monotherapy. ㆍ10/160 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or valsartan 160 mg monotherapy, or with 5/160 mg. - Patients with renal impairment: No dosage adjustment is required in patients with mild or moderate renal impairment (creatinine clearance 10mL/min or more); however, the amlodipine/valsartan combination should not be administered to patients with severe renal impairment (creatinine clearance less than 10mL/min) or patients on dialysis. Monitoring of potassium levels and creatinine is recommended in patients with moderate renal impairment. - Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of valsartan should not exceed 80mg. Do not administer the amlodipine/valsartan combination to patients with severe hepatic impairment, biliary cirrhosis, biliary obstruction, or cholestasis. - Patients aged 65 years or older: Use caution when increasing the dose. ▷ Atorvastatin Before and during treatment with atorvastatin, patients should follow a standard cholesterol-lowering diet. Atorvastatin may be taken at any time of day, with or without food. 1. Dyslipidemia The recommended initial dose is 10 mg of atorvastatin once daily. However, patients who require a greater reduction in LDL cholesterol may start with 20 mg or 40 mg once daily (40 mg is for patients requiring an LDL cholesterol reduction of 45 % or more). This medicine is administered at a dose of 10 ~ 80 mg once daily. The initial and maintenance doses should be individualized according to the patient's characteristics, taking into account the treatment goal and response. Lipid levels should be analyzed within 2 ~ 4 weeks after treatment initiation and/or dose titration, and the dose should be adjusted accordingly. Because the goal of treatment is to lower LDL cholesterol, it is recommended that LDL cholesterol be used when initiating treatment and assessing the treatment response. However, if LDL cholesterol levels are unavailable, total cholesterol should be used to monitor the treatment response. Patients with homozygous familial hypercholesterolemia The dose is 10 ~ 80 mg once daily. Administer this medicine in combination with other lipid-lowering treatments (e.g., LDL apheresis), or when such treatments are not possible. - Patients with renal impairment: Renal disease does not affect the plasma concentration of atorvastatin or its LDL cholesterol-lowering effect; therefore, no dosage adjustment is necessary. - Older adults: The efficacy and safety in patients aged 70 years or older are similar to those in the general adult population.

Precautions

This medication can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters; therefore, it should be discontinued immediately upon confirmation of pregnancy. If muscle-related abnormal symptoms appear or if muscle enzyme levels significantly increase, discontinuation of this medication is advised, as severe myopathy may lead to renal function decline. This medication should not be administered to patients with certain conditions, such as severe hepatic impairment, severe renal impairment, hereditary angioedema, or severe myopathy. In patients with hypotension or fluid depletion, their condition must be confirmed before administration, and blood pressure and fluid status should be closely monitored during treatment. Patients with high potassium levels should be very cautious when taking this medication alongside potassium-increasing medications or supplements, and serum potassium levels should be checked frequently. Due to insufficient experience with this medication in kidney transplant patients or those with renal artery stenosis, careful consideration should be taken. If symptoms of angioedema appear, this medication should be discontinued immediately, and consultation with a healthcare professional is necessary; re-administration should be avoided. In patients with heart failure or after a myocardial infarction, blood renal function and blood pressure changes must be monitored closely during administration, and caution is required during initiation or dose escalation in acute myocardial infarction patients. This medication requires dose adjustment in patients with impaired liver function, and if liver function tests or hepatitis symptoms occur, treatment should be stopped immediately. Patients should be aware that dizziness or fatigue may occur while driving or operating machinery. If symptoms such as muscle pain, muscle weakness, or fever occur while taking this medication, immediate consultation with a doctor is required, and muscle enzyme testing should be conducted to check for muscle damage. This medication may interact with other drugs; therefore, patients must inform their healthcare provider of any concomitant medications, especially when taking specific antibiotics, antifungals, antivirals, diuretics, or potassium-sparing agents. Pregnant or breastfeeding women should not take this medication, and women of childbearing potential should use appropriate contraceptive methods during treatment. This medication contains lactose, so patients with lactose intolerance should not take it. It is important to regularly monitor blood pressure, liver function, kidney function, serum potassium levels, and muscle status during therapy.

Side effects

  • Dry eyes
  • nausea
  • headache
  • nasopharyngitis
  • influenza
  • hypersensitivity
  • visual impairment
  • anxiety
  • dizziness
  • drowsiness
Show 140 more
  • positional dizziness
  • paresthesia
  • vertigo
  • tinnitus
  • tachycardia
  • palpitations
  • syncope
  • orthostatic hypotension
  • hypotension
  • cough
  • pharyngeal and laryngeal pain
  • diarrhea
  • abdominal pain
  • constipation
  • thirst
  • rash
  • erythema
  • hyperhidrosis
  • itching
  • joint swelling
  • low back pain
  • arthritis
  • muscle cramps
  • weakness
  • frequency of urination
  • polyuria
  • erectile dysfunction
  • edema
  • pedaled edema
  • facial edema
  • peripheral edema
  • fatigue
  • flushing
  • asthenia
  • facial flushing
  • diplopia
  • thrombocytopenia
  • leukopenia
  • allergic reaction
  • hyperglycemia
  • insomnia
  • mood changes
  • tremors
  • taste disturbance
  • peripheral neuropathy
  • muscle tension
  • arrhythmia
  • bradycardia
  • atrial fibrillation
  • ventricular tachycardia
  • myocardial infarction
  • vasculitis
  • dyspnea
  • rhinitis
  • vomiting
  • dyspepsia
  • pancreatitis
  • gastritis
  • hepatitis
  • jaundice
  • alopecia
  • purpura
  • skin depigmentation
  • photosensitivity reaction
  • angioedema
  • urticaria
  • erythema multiforme
  • myalgia
  • urination disorders
  • nocturia
  • gynecomastia
  • pain
  • malaise
  • weight loss
  • weight gain
  • hemoglobin decrease
  • hematocrit decrease
  • neutropenia
  • serum sickness
  • increased serum potassium
  • renal failure
  • kidney damage
  • elevated serum creatinine
  • weakness
  • chest pain
  • fatigue
  • fever
  • hyperglycemia
  • hypoglycemia
  • weight gain
  • anorexia
  • abdominal distention
  • belching
  • pharyngeal and laryngeal pain
  • epistaxis
  • nightmares
  • perceptual disturbances
  • amnesia
  • peripheral neuropathy
  • muscle spasms
  • muscle fatigue
  • rupture-related complications
  • myopathy
  • myositis
  • rhabdomyolysis
  • tendon disorders
  • muscle rupture
  • lupus-like syndrome
  • immune-mediated necrotizing myopathy
  • anaphylaxis
  • cholestasis
  • liver failure
  • blurred vision
  • tinnitus
  • hearing loss
  • angioedema
  • erythema multiforme
  • mucocutaneous syndrome
  • toxic epidermal necrolysis
  • gynecomastia
  • abnormal liver function tests
  • increased serum CK
  • positive urinary leukocytes
  • chest discomfort
  • abdominal discomfort
  • gastroesophageal reflux disease
  • neck pain
  • hypercholesterolemia
  • hypoglycemia
  • nocturia
  • chest pain
  • weight gain
  • arthralgia
  • skeletal pain
  • rhabdomyolysis
  • gingival hyperplasia
  • gastritis
  • nervous hyperactivity
  • sensory impairment
  • Stevens-Johnson syndrome

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly sealed container to prevent air or moisture from entering. Additionally, it is recommended to store the medication at room temperature between 1 to 30 degrees Celsius to ensure its effectiveness.

Appearance and packaging

Appearance

Pale orange, oval film-coated tablet

Package unit

30 tablets per bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.